Don't Forget First to Market!18 Jun 2021 07:29
Yes, we know that the SP is being manipulated big time and is painful to watch and during this time a few poster on here then start to ask for "Heads" on a platter, but I would suggest when seeds of doubt start to creep in refer back to some of the great work being done by those "Heads" - The amount of plates these "Heads" must be spinning in order to role out products where their main objective is to make the world a safer place for all of us and on top of the innovation and bringing products to market but also dealing with the politics!
NO Business is built overnight and particularly one where the products are so complex and peoples lives depend and getting this right - just remember that when you think your having a bad day.
SNPsig® EscapePLEX SARS-CoV-2 is a first-to-market assay panel in a single kit able to detect the four most critical SARS-CoV-2 mutations currently recognised, combined with a confirmatory two-gene assay for COVID-19. The research-use-only kit detects the biologically significant 'escape' mutations E484K, K417N, K417T and P681R, present in the Alpha, Beta, Gamma and Delta Variants[1] of Concern (VoC), and also incorporates the two gene (ORF1ab and M) assay to provide a confirmatory detection of SARS-CoV-2.
About the SNPsig® portfolio
Novacyt's bioinformatics surveillance group remains highly vigilant and, as new biologically significant mutations are identified, these will continue to be added to the SNPsig® portfolio. A recent study reported in the medRxiv5, the preprint server for health sciences, demonstrates the high potential of the SNPsig® portfolio to detect the most significant mutations, VoCs and variants.
Graham Mullis, Chief Executive Officer of Novacyt, commented:
"The success of our COVID-19 PCR assays has been built around robust design principles and our real-time bioinformatics surveillance programme to monitor new SARS-CoV-2 genome sequences. As a result, our genesig® COVID-19 portfolio is highly accurate despite mutations, and we believe our SNPsig® portfolio is the world's largest for detecting SARS-CoV-2 variants. The addition of both of these new assays ensures that Novacyt's COVID-19 solutions remain robust and that pragmatic options are available to support both public health and private sector testing alike."
"We are very pleased to be included in NHS England's VoC Framework, which allows our SNPsig® range of products to be used at any NHS and Lighthouse laboratories, subject to local verification, as we continue to support diagnostic testing across the UK, and globally, through our extensive portfolio. We remain committed to developing new tests to match the rapid evolution of the SARS-CoV-2 virus with our real-time bioinformatics surveillance programme and accelerated product development. Our SNPsig® portfolio for detecting Variants of Interest and Variants of Concern now includes 12 individual assays to support scientists and clinicians in the ongoing fight against COVID-
Sign In
Follow the stocks
